FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to endocrinology and can be used for diagnosing coronary artery calcinosis in a patient with secondary hyperparathyroidism. Content of intact parathyroid hormone, calcium, phosphorus is determined in patient's blood serum; patient's age is taken into account. Calcification level (LC) is determined by the original calculation formula and when the value LC is greater than 0 establish the presence of calcification, and at a value equal to LC and less than 0 – no calcification.
EFFECT: method enables extending the diagnostic capabilities of coronary artery calcinosis in the patients with secondary hyperparathyroidism receiving the renal replacement therapy by hemodialysis, while having ease of implementation, does not require specialized equipment and instruments and does not carry a radiological load on the body of the patient.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SCREENING DIAGNOSTIC TECHNIQUE FOR ARTERIOVENOUS FISTULA STENOSIS IN PATIENTS WITH END-STAGE CHRONIC RENAL DISEASE | 2012 |
|
RU2508544C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPMENT OF ACUTE KIDNEY INJURY IN PATIENTS AFTER PARATHYROIDECTOMY FOR PRIMARY HYPERPARATHYROIDISM | 2020 |
|
RU2781110C2 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR PARATHYROID HYPERPLASIA IN PATIENTS WITH HYPERPARATHYROIDISM | 2014 |
|
RU2561031C1 |
| METHOD OF TREATING POSTOPERATIVE HYPOPARATHYROIDISM AFTER SURGERY IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM | 2023 |
|
RU2817205C1 |
| METHOD FOR EXAMINING QUALITY OF EXTRARENAL BLOOD CLEARANCE | 1998 |
|
RU2155074C2 |
| METHOD FOR PREDICTION OF RISK OF CALCIFICATION OF BIOLOGICAL PROSTHESES OF CARDIAC VALVES | 2015 |
|
RU2597564C1 |
| METHOD OF DIAGNOSING β2 MICROGLOBULIN AMYLOIDOSIS IN PATIENTS WITH CHRONIC KIDNEY DISEASE OF FIFTH STAGE WHO ARE ON RENAL REPLACEMENT THERAPY | 2012 |
|
RU2500352C1 |
| METHOD FOR DIAGNOSTICS OF BODY ENDOTOXICOSIS DEGREE | 2001 |
|
RU2190851C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR SECONDARY AND TERTIARY HYPERPARATHYROID | 2013 |
|
RU2542456C1 |
| USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM | 2013 |
|
RU2666995C2 |
